UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.09.24 | Real-time BOERSE MUENCHEN 05:11:18 04/06/2024 pm IST | ||
| 0.54 EUR | 0.00% |
|
| Current month | +38.46% | ||
| 1 month | +237.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 0.54 | 0.00% |
| 03/24/03 | 0.54 | +38.46% |
| 31/24/31 | 0.39 | +30.00% |
| 30/24/30 | 0.3 | -14.29% |
| 29/24/29 | 0.35 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 04, 2024 at 05:11 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD0BHZ |
| ISIN | DE000HD0BHZ7 |
| Date issued | 31/10/2023 |
| Strike | 550 $ |
| Maturity | 18/09/2024 (106 Days) |
| Parity | 10 : 1 |
| Emission price | 0.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.82 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.1 € |
| Spread % | 16.13% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.2
USD
Average target price
463.5
USD
Spread / Average Target
-1.41%
- Stock Market
- Warrants
- Warrant
